SCI Pharmtech Inc logo

4119 - SCI Pharmtech Inc Share Price

TWD123 0.0  0.0%

Last Trade - 18/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £258.8m
Enterprise Value £220.7m
Revenue £70.4m
Position in Universe 1691st / 5985
Bullish
Bearish
Unlock 4119 Revenue
Momentum
Relative Strength (%)
1m -1.24%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -21.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
1,492 1,811 1,903 1,301 1,940 2,356 2,697 2,720 +9.6%
+64.8 +39.4 +9.1 -54.2 +132.8 +28.1 +30.0 -6.09
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, SCI Pharmtech Inc revenues increased 25% to NT$1.51B. Net income increased 40% to NT$450M. Revenues reflect Active Pharmaceutical Ingredients segment increase of 45% to NT$555.8M, Other Foreign segment increase of 90% to NT$315.3M, Italy segment increase of 33% to NT$250.4M. Net income benefited from Loss on Disposal of Fixed Assets increase from NT$1.6M (expense) to NT$29K (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 4119
Graphical History

Revenue

4119 Revenue Unlock 4119 Revenue

Net Income

4119 Net Income Unlock 4119 Revenue

Normalised EPS

4119 Normalised EPS Unlock 4119 Revenue

PE Ratio Range

4119 PE Ratio Range Unlock 4119 Revenue

Dividend Yield Range

4119 Dividend Yield Range Unlock 4119 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
4119 EPS Forecasts Unlock 4119 Revenue
Profile Summary

SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated September 18, 1987
Public Since August 12, 2002
No. of Shareholders: 21,596
No. of Employees: 241
Sector Healthcare
Industry Pharmaceuticals
Index Taiwan SE Weighted ,
Exchange Taiwan Stock Exchange
Shares in Issue 79,485,300
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4119 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4119
Upcoming Events for 4119
Frequently Asked Questions for SCI Pharmtech Inc
What is the SCI Pharmtech Inc share price?

As of 18/09/20, shares in SCI Pharmtech Inc are trading at TWD123, giving the company a market capitalisation of £258.8m. This share price information is delayed by 15 minutes.

How has the SCI Pharmtech Inc share price performed this year?

Shares in SCI Pharmtech Inc are currently trading at TWD123 and the price has moved by 20% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the SCI Pharmtech Inc price has moved by 19.75% over the past year.

What are the analyst and broker recommendations for SCI Pharmtech Inc?

Of the analysts with advisory recommendations for SCI Pharmtech Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for SCI Pharmtech Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will SCI Pharmtech Inc next release its financial results?

SCI Pharmtech Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the SCI Pharmtech Inc dividend yield?

The SCI Pharmtech Inc dividend yield is 4.72% based on the trailing twelve month period.

Does SCI Pharmtech Inc pay a dividend?

Last year, SCI Pharmtech Inc paid a total dividend of 5.8, and it currently has a trailing dividend yield of 4.72%. Looking ahead, SCI Pharmtech Inc has not announced an ex-dividend date yet.

When does SCI Pharmtech Inc next pay dividends?

SCI Pharmtech Inc has yet to annouce their ex-dividend date. The historic dividend yield on SCI Pharmtech Inc shares is currently 4.72%.

How do I buy SCI Pharmtech Inc shares?

To buy shares in SCI Pharmtech Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of SCI Pharmtech Inc?

Shares in SCI Pharmtech Inc are currently trading at TWD123, giving the company a market capitalisation of £258.8m.

Where are SCI Pharmtech Inc shares listed? Where are SCI Pharmtech Inc shares listed?

Here are the trading details for SCI Pharmtech Inc:

Country of listing: Taiwan
Exchange: TAI
Ticker Symbol: 4119
What kind of share is SCI Pharmtech Inc?

Based on an overall assessment of its quality, value and momentum, SCI Pharmtech Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a SCI Pharmtech Inc share price forecast 2020?

Shares in SCI Pharmtech Inc are currently priced at TWD123. At that level they are trading at 13.01% discount to the analyst consensus target price of 0.00.

Analysts covering SCI Pharmtech Inc currently have a consensus Earnings Per Share (EPS) forecast of 9.275 for the next financial year.

How can I tell whether the SCI Pharmtech Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SCI Pharmtech Inc. Over the past six months, the relative strength of its shares against the market has been -11.95%. At the current price of TWD123, shares in SCI Pharmtech Inc are trading at -0.69% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the SCI Pharmtech Inc PE Ratio?

The SCI Pharmtech Inc PE ratio based on its reported earnings over the past 12 months is 14.08. The shares are currently trading at TWD123.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of SCI Pharmtech Inc?

SCI Pharmtech Inc's management team is headed by:

Shiang-Li Chen - DRC
Wei-Chyun Wong - CHM
Guifang She - DGM
Wenzhi Zhou - DRC
Wenzhen Yang - FID
Kelin Feng - DRC
Yanru Chen - DRC
Jiajun Chen - IND
Who are the major shareholders of SCI Pharmtech Inc?

Here are the top five shareholders of SCI Pharmtech Inc based on the size of their shareholding:

Mercuries & Associates Holding Ltd Corporation
Percentage owned: 31.75% (25.2m shares)
SCI Pharmtech Inc. ESOP Corporation
Percentage owned: 2.43% (1.93m shares)
Mercury Fu Bao Company Ltd. Corporation
Percentage owned: 2.29% (1.82m shares)
Ensign Peak Advisors, Inc. Foundation
Percentage owned: 1.78% (1.42m shares)
Mackenzie Financial Corporation Investment Advisor/Hedge Fund
Percentage owned: 1.51% (1.20m shares)
Similar to 4119
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.